Featured Archives - Race Oncology

Race Oncology is pleased to announce that approval has been received from the Medicines and

Race Oncology is pleased to announce a case report describing the successful use of Bisantrene

Race Oncology Non-Executive Director Dr. John Cullity speaks with Proactive Investors about the

New Race non-executive director Dr John Cullity has used his first interview to highlight the

Race Oncology has announced it has executed a global distribution agreement with UK-based,

Race Oncology is pleased to announce the appointment of US-based Dr John Cullity as a

In a major development for the Australian biotech sector, ASX-listed oncology drug developer,

Race Oncology has released its Investor Presentation ahead of CEO Peter Molloy’s address

A key Bisantrene patent has received “Notice of Allowance” in the United States,

Date	Title
03/08/2018	Investor Presentation	Download
27/07/2018	June 2018 Quarterly Report	Download
18/07/2018	FDA Grants Bisantrene Rare Paediatric Disease Designation	Download
16/07/2018	Trading Halt	Download
13/07/2018	Appendix 3B-Issue of Options	Download
13/07/2018	Appendix 3B	Download
02/07/2018	Cleansing Notice	Download
02/07/2018	Appendix 3B	Download
02/07/2018	Expiry of Unlisted Options	Download
02/07/2018	Performance Share Milestones Met	Download